Adverse drug reactions requirements

Adverse drug reaction is an undesired or unintended effect of the drug, occurs at dose normally used by human being. The adverse drug reaction requires treatment or decrease in dose if it is due to poisoning or overdose. 

Clinical evaluation of adverse drug reactions requires careful assessment of the patient and... 

Monitoring and Managing Adverse Drug Reactions The nurse observes the patient at frequent intervals, especially during the first 48 hours of therapy. It is important to report to the primary health care provider the occurrence of any adverse reaction before the next dose of the drug is due The nurse should report serious adverse reactions, such as a severe hypersensitivity reaction, respiratory difficulty, severe diarrhea, or a decided drop in blood pressure, to the primary health care provider immediately because a serious adverse reaction may require emergency intervention. 

Risk for Imbalanced Nutrition Less Than Body Requirements related to adverse drug reactions or disease process (malaria)... 

Monitoring and Managing Adverse Drug Reactions The nurse observes the patient for adverse drug reactions because their occurrence may require a change in the dose or the drug. The nurse should notify the primary care provider if any adverse reactions occur, hi some instances, the patient may have to tolerate mild adverse reactions, such as dry mouth or mild anorexia... 

ASSESSMENT OF THE HOSPITALIZED PATIENT The hospitalized patient receiving a female hormone requires careful monitoring. The nurse takes the vital signs daily or more often, depending on the patient s physical condition and the reason for drug use. The nurse observes the patient for adverse drug reactions, especially those related to the liver (the development of jaundice) or the cardiovascular system (thromboembolism). The nurse weighs the patient weekly or as ordered by the primary health care provider. The nurse... 

Niacin has many common adverse drug reactions most of the symptoms and biochemical abnormalities seen do not require discontinuation of therapy. 

Adverse drug reactions are mostly dose related and therefore it is important to choose the lowest dose required for beneficial effect. 

WHO (1975). Requirements for Adverse Drug Reaction Reporting. WHO, Geneva. 

Approximately 10% of new chemical entities (NCEs) show serious adverse drug reactions (ADRs) after market launch. Such events usually result in new black box warnings by the US Food and Drug Administration (FDA), label change or market withdrawal. The most common causes for these actions are hepatic toxicity, hematologic toxicity and cardiovascular toxicity [2], Reasons for such ADRs, which are identified only after NCEs are launched on the market, include the narrow spectrum of clinical disorders and participating patient profiles in clinical studies as well as the fact that serious ADRs are often rare and that the number of patient exposures required to identify such occurrences sometimes may range over a few millions [3],... 

CIOMS. Basic requirements for the use of terms for reporting adverse drug reactions. Pharmacoepidemiol Drug Safety 1992 1 39-45. 

Article 102 includes a provision that requires Member States to share information collected through their pharmacovigilance system with other Member States and the EMEA. The central database EudraVigilance has been developed to allow Member States and the EMEA to share information on adverse drug reactions once all Member States have populated it. 

The standard conditions of registration require the sponsor to inform the TGA of any adverse drug reactions and safety alerts related to their product of which they become aware. 

The requirements for reporting adverse drug reactions to prescription medicines occurring in Australia or overseas are described in the Australian Pharmacovigilance Guidehne, which is available at the TGA website. 

Sponsors are not required, as a matter of routine, to submit individual patient reports to the TGA of suspected adverse drug reactions occurring with use of the same product in another country, even if a trial is ongoing at Australian sites. However, the TGA requires that sponsors advise the Experimental Drugs Section of DSEB within 72 h of any significant safety issue which has arisen from an analysis of overseas reports or action with respect to safety taken by another country s regulatory agency. This advice must include the basis for such action. 

Severe, life-threatening diseases, such as cancer require a different drug discovery approach. Safety requirements in most oncology targets tolerate more side effects, which otherwise would severely limit the use of a medicine in other indications. For example, in addition to hair loss, a common side effect of cancer treatment, compounds which affect cell cycle, cell proliferation and apoptosis pathways also cause other serious side effects and make the patient endure severe adverse drug reactions (ADRs). 

Reporting of suspicions of dependence should be to the national adverse drug reaction centre, but other reporting requirements under national laws must be followed. 

---